Home
Who We Are
What We Do
Corporate Responsibility
News
Careers
Investors
Patients and HCPS
Contact us
Careers | Investors | Patients and HCPS | Contact us
Careers Investors Patients and HCPS Contact us
Home / Company News / Preview of Meeting | Gan & Lee Pharmaceuticals presents at American Diabetes Association’s 84th Scientific Sessions – A Convergence of Global Leaders in Diabetes Research and Care
Preview of Meeting | Gan & Lee Pharmaceuticals presents at American Diabetes Association’s 84th Scientific Sessions – A Convergence of Global Leaders in Diabetes Research and Care
Date:2024-05-28

Event Overview

Mark your calendars for the American Diabetes Association's 84th Scientific Sessions, to be held from June 21-24, 2024, at the Orange County Convention Center in Orlando, Florida. This flagship assembly promises to advance the global mission of the ADA: to prevent and cure diabetes and to improve the lives of all people affected by this condition.


Conference Highlights

The 2024 sessions will continue to drive innovation and collaboration across the spectrum of diabetes research and care. Expect a comprehensive lineup of the latest scientific advances and ground-breaking research presentations. This year, the focus will be on the most relevant topics in both basic and translational science, aiming to challenge current treatment paradigms and push the boundaries of knowledge.

 

Engagement Opportunities

Attendees will benefit not just from the sessions but also from the ability to participate in discussions with global leaders in research and healthcare, engage in multidisciplinary interactions, and explore the latest innovations in the exhibit hall that runs concurrently with the conference.

 

Networking and Exhibitions

The event is set to host approximately 10,000 in-person attendees and 1,700 online participants, offering an unparalleled opportunity for professionals from around the world to network, share insights, and discuss future advancements in diabetes care. The conference will also feature an expansive trade show with exhibitors from across the diabetes care spectrum, showcasing new solutions and technologies. Gan & Lee Pharmaceuticals, a leading pharmaceutical un the field of diabetes treatment in China, is going to hold an exhibit booth during the scientific sessions. Join us in Orlando, FL for the World’s Premier Meeting on Diabetes! 


Gan & Lee Pharmaceuticals Booth Information

American Diabetes Association’s 84th Scientific Sessions

Time: June 22-24, 2024, 10:00 a.m. -4:00 p.m.

Location: Exhibit Hall, Orange Cunty Convention Center

Booth Number: #1710


For more detailed information and to register, please visit the official ADA Scientific Sessions website. Join us in Orlando to be a part of a vibrant scientific community working towards a life free from diabetes and its burdens.。

 

American Diabetes Association (ADA)

The American Diabetes Association (ADA) is a leading force in the global fight against diabetes, focusing on a broad range of activities to prevent, cure, and manage diabetes. Established with the mission to improve the lives of all people affected by diabetes, the ADA conducts research, delivers services to communities, provides credible information, and advocates for the rights of people affected by diabetes. Through its extensive network of volunteers, healthcare professionals, and staff, the ADA organizes conferences, publishes scientific research, sets clinical guidelines, and educates healthcare providers and the public about diabetes. Its initiatives also include fundraising for diabetes research, public awareness campaigns, and support for individuals with diabetes and their families. The organization's efforts aim to ensure better health outcomes and a better quality of life for those living with diabetes. For more information about the ADA and its various programs, visit their official website.

 

References:

1.    American Diabetes Association. https://diabetes.org/

2.    ADA’s 84th Scientific Sessions. https://professional.diabetes.org/scientific-sessions

 

About Gan & Lee


Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).


In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.


 


Copyright © 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP备10213074号-1 | 京公网安备 11011202003900号
Our websites

Subscribe

I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.